TransMedics Group (NASDAQ:TMDX – Get Free Report) released its quarterly earnings data on Monday. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17), Briefing.com reports. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The company had revenue of $108.76 million for the quarter, compared to analysts’ expectations of $115.00 million. During the same period last year, the company posted ($0.12) EPS. The business’s revenue for the quarter was up 63.7% compared to the same quarter last year. TransMedics Group updated its FY 2024 guidance to EPS.
TransMedics Group Stock Down 0.6 %
Shares of NASDAQ:TMDX traded down $0.46 during midday trading on Thursday, reaching $81.46. The company’s stock had a trading volume of 718,189 shares, compared to its average volume of 929,908. The company has a quick ratio of 8.48, a current ratio of 9.37 and a debt-to-equity ratio of 2.67. The firm has a 50 day moving average of $144.20 and a 200-day moving average of $139.76. The firm has a market capitalization of $2.72 billion, a P/E ratio of 87.15 and a beta of 1.99. TransMedics Group has a 12-month low of $36.42 and a 12-month high of $177.37.
Wall Street Analysts Forecast Growth
Several brokerages have weighed in on TMDX. Oppenheimer cut their price target on shares of TransMedics Group from $200.00 to $125.00 and set an “outperform” rating on the stock in a report on Tuesday. Robert W. Baird cut their target price on TransMedics Group from $200.00 to $150.00 and set an “outperform” rating on the stock in a research note on Tuesday. Canaccord Genuity Group reduced their price target on TransMedics Group from $169.00 to $109.00 and set a “buy” rating on the stock in a report on Tuesday. Needham & Company LLC dropped their price objective on TransMedics Group from $208.00 to $109.00 and set a “buy” rating for the company in a report on Tuesday. Finally, Piper Sandler reissued an “overweight” rating and set a $180.00 target price on shares of TransMedics Group in a research note on Tuesday. One analyst has rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $144.80.
Insider Activity at TransMedics Group
In other TransMedics Group news, Director Edward M. Basile sold 6,750 shares of the firm’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $149.96, for a total transaction of $1,012,230.00. Following the completion of the transaction, the director now owns 732 shares of the company’s stock, valued at approximately $109,770.72. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Edward M. Basile sold 6,750 shares of the company’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $149.96, for a total transaction of $1,012,230.00. Following the completion of the sale, the director now owns 732 shares of the company’s stock, valued at $109,770.72. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Waleed H. Hassanein sold 8,625 shares of the business’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $132.71, for a total transaction of $1,144,623.75. Following the completion of the sale, the chief executive officer now owns 61,643 shares in the company, valued at $8,180,642.53. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 61,247 shares of company stock valued at $9,518,181 in the last three months. Company insiders own 7.00% of the company’s stock.
About TransMedics Group
TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Featured Articles
- Five stocks we like better than TransMedics Group
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Microsoft Can Hit New All-Time Highs This Year – Here’s Why
- P/E Ratio Calculation: How to Assess Stocks
- Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- IonQ’s Quantum Surge: Ride the Wave or Cash Out?
Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.